Publications by authors named "Jianchang Lin"

Claim this Profile
A
An Anti-Inflammatory and Pro-Angiogenic Porous Aloe Polysaccharide-Collagen Dressing Accelerates Wound Healing.
Qiong Jiang, MinShi Li, DanHong Chen, JianChang Lin, Pei Wei

ACS Appl Bio Mater· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
M-DODII: Bayesian dose optimization design for randomized phase II study with multiple indications.
Sasha Amdur Kravets, Ziji Yu, Rachael Liu, Jianchang Lin

J Biopharm Stat· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO.
Arvind Dasari, Cathy Eng, Sara Lonardi, Rocio Garcia-Carbonero, Toshiki Masuishi, Chiara Cremolini, Lin Shen, Jianchang Lin

Eur J Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BARD: A seamless two-stage dose optimization design integrating backfill and adaptive randomization.
Yixuan Zhao, Rachael Liu, Jianchang Lin, Ying Yuan

Clin Trials· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Flexible Seamless Phase 2/3 Design With Biomarker-Driven Subgroup Enrichment and Sample Size Re-Estimation.
Zizhong Tian, Liwen Wu, Rachael Liu, Jianchang Lin

Pharm Stat· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An adaptive seamless 2-in-1 design with biomarker-driven subgroup enrichment.
Liwen Wu, Jianchang Lin

J Biopharm Stat· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BEAM: Bayesian Hybrid Design With Adaptive Sample Size Through Multisource Exchangeability Modeling.
Feng Tian, Meizi Liu, Yunqi Zhao, Jianchang Lin, Rachael Liu

Stat Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial.
Pasi A Jänne, Bin-Chao Wang, Byoung Chul Cho, Jun Zhao, Juan Li, Junjing Lin, Jianchang Lin, Huamao M Lin

J Clin Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing Quality Tolerance Limits Monitoring in Clinical Trials Through Machine Learning Methods.
Lei Yan, Ziji Yu, Liwen Wu, Rachael Liu, Jianchang Lin

Ther Innov Regul Sci· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Information Extraction with Large Language Models: A Case Study on Organ Procurement.
Hammaad Adam, Junjing Lin, Jianchang Lin, Hillary Keenan, Ashia Wilson

AMIA Annu Symp Proc· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations for master protocols using external controls.
Jie Chen, Xiaoyun Nicole Li, Chengxing Cindy Lu, Sammy Yuan, Godwin Yung, Jianchang Lin

J Biopharm Stat· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DOD-SSR: An Adaptive Seamless Phase II/III Design With Dose Optimization Decision and Sample Size Re-estimation.
Meizi Liu, Jianchang Lin, Yefei Zhang, Rachael Liu

Stat Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bayesian model averaging for randomized dose optimization trials in multiple indications.
Wei Wei, Jianchang Lin

J Biopharm Stat· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multiple imputation approach in enhancing causal inference for overall survival in randomized controlled trials with crossover.
Ruochen Zhao, Junjing Lin, Jing Xu, Guohui Liu, Bingxia Wang, Jianchang Lin

J Biopharm Stat· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DOD-BART: machine learning-based dose optimization design incorporating patient-level prognostic factors via Bayesian additive regression trees.
Yunqi Zhao, Rachael Liu, Jianchang Lin, Andy Chi, Simon Davies

J Biopharm Stat· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incorporating external real-world data (RWD) in confirmatory adaptive design.
Junjing Lin, Jianchang Lin

J Biopharm Stat· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flexible seamless 2-in-1 design with sample size adaptation.
Runjia Li, Liwen Wu, Rachael Liu, Jianchang Lin

J Biopharm Stat· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Covariate adjusted meta-analytic predictive (CA-MAP) prior for historical borrowing using patient-level data.
Bradley Hupf, Yunlong Yang, Ryan Gryder, Veronica Bunn, Jianchang Lin

J Biopharm Stat· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants.
Michael J Hanley, Steven Zhang, Robert Griffin, Sean Xiaochun Zhu, Robert J Fram, Jianchang Lin

Invest New Drugs· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.
Sai-Hong Ignatius Ou, Thibaud Prawitz, Huamao M Lin, Jin-Liern Hong, Min Tan, Jianchang Lin

Clin Lung Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling.
Wei Wei, Ondrej Blaha, Denise Esserman, Daniel Zelterman, Michael Kane, Jianchang Lin

Stat Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preparation and efficacy verification of three-dimensional printed partitioned multi-effect precision-care gel facial mask.
Junli Chen, Chunqiao Liufu, Wenfang Zhang, Chunhong Luo, Kaixia Fu, Jianchang Lin

Int J Cosmet Sci· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DOD-Combo: Bayesian dose finding design in combination trials with meta-analytic-predictive prior.
Kai Chen, Yunqi Zhao, Meizi Liu, Jianchang Lin, Rachael Liu

J Biopharm Stat· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BEATS: Bayesian hybrid design with flexible sample size adaptation for time-to-event endpoints.
Dehua Bi, Meizi Liu, Jianchang Lin, Rachael Liu

Stat Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical value of neutrophil-to-lymphocyte ratio and prognostic nutritional index on prediction of occurrence and development of diabetic foot-induced sepsis.
Bing Sun, Yimin Chen, Yulin Man, Yu Fu, Jianchang Lin

Front Public Health· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis